Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Anne Wojcicki
since
auto-detected in 4 stories
7 months ago
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
10 months ago
Genetic data is an another asset to be exploited – beware who has yours | John Naughton ○
found
a story from The Guardian ⚠️ › International
The bankruptcy of genealogy company 23andMe has resulted in a fire sale of millions of people’s genetic information – and there’s no shortage of eager buyers with questionable motives
Ever thought of …
11 months ago
As a geneticist, I will not mourn 23andMe and its jumble of useless health information | Adam Rutherford ○
found
a story from The Guardian ⚠️ › International
Millions paid to give away their most personal data. At least in return they found out more about their earwax
Information is the most valuable resource on Earth. We shed data from everything that we …
From spit to bankruptcy: the rise and fall of 23andMe ○
Plus: Nvidia bets on AI-powered robots, Musk juggles Tesla and politics, and AI fiction takes over Instagram
Hello, and welcome to TechScape. In this week’s edition: 23andMe files for bankruptcy, Nvid…
page 1 of 1